Natural History of Autoimmune Diabetes and Its Complications
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Background:
- Diabetes is a disease defined by abnormally high blood sugar (glucose) levels. Glucose is an essential source of energy for the body's cells, but insulin is required to move the glucose into the cells. Insulin is a hormone produced by the pancreas that allows glucose to enter cells.
- In diabetes, the body is unable to supply enough insulin to meet its demands. The problem may be a low supply of insulin or a high demand for insulin. Someone who has been diagnosed with diabetes has lost much of their insulin-producing capacity. Clinical studies have shown that good control of blood sugar is essential to prevent diabetes complications like damage to the eyes, kidneys, nerves, and blood vessels.
Objectives:
- To establish a relationship with several individuals with diabetes caused by the immune system attacking the body's insulin-producing cells in order to:
- Explore why the immune system attacks insulin-producing cells.
- Understand why some individuals develop diabetes-related complications and others do not.
- Develop therapies to improve how patients can control their blood sugar levels.
- Continue to follow subjects who have completed or are considering other NIH diabetes-related studies.
- To develop improved tests for determining an individual's risk for developing diabetes and/or to accurately diagnose the exact type of diabetes.
Eligibility:
- Individuals who have been diagnosed with or are at risk for developing diabetes.
Design:
- Standard physical examination and clinical tests to determine if the patient has diabetes or to confirm a particular type of diabetes:
- None of the treatment in this study is experimental.
- Patients will receive a separate consent form for any special tests needed to learn more about their particular type of diabetes.
- Patients may be asked to provide additional urine and blood samples for use in laboratory research about diabetes.
- Researchers may offer medical treatment advice for diabetes, or explain how to improve patients' diabetes management skills.
| Condition |
|---|
|
Type 1 Diabetes Type 2 Diabetes Immunologically Mediated Type 1 Diabetes Anti Beta-Cell Autoantibodies Autoimmunity |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | Natural History of Autoimmune Diabetes and Its Complications |
| Estimated Enrollment: | 99999999 |
| Study Start Date: | May 2009 |
Individuals with known or suspected autoimmune mediated diabetes, or healthy individuals at risk for developing the disease, will be evaluated at the NIH Clinical Center. Studies will include characterizing the disease's clinical and laboratory features, observing the natural history of the disease and its complications, evaluating responses to standard treatments, designing assays to measure anti-insulin producing cell immune responses and pancreatic insulin producing cell function and number, and determining patients' eligibility for other experimental diagnostic or therapeutic protocols. Protocol enrollees may be asked to contribute blood and/or urine samples for immunological research studies, and/or for studies designed to find parameters that increase a subject's risk for diabetes and/or its associated complications.
Eligibility| Ages Eligible for Study: | 2 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
-INCLUSION CRITERIA:
i. Clinical diagnosis of diabetes, either type 1 (T1D) or insulin-requiring type 2 (T2D),
ii. Healthy individuals who may be at risk for developing diabetes,
iii. Individuals with suspected immune mediated diabetes,
iv. Willingness of the patient or guardian to give informed consent and assent.
EXCLUSION CRITERIA:
i. Concomitant medical problems which would confound the interpretation studies of the autoimmune beta cell destructive process
ii. Concomitant medical, surgical, or other conditions for which adequate facilities or funds are not available to support their care at the NIH.
iii. Any other co-existing condition/circumstances that would make a subject unsuitable to participate in the study, as deemed by the investigators.
Contacts and Locations| Contact: Monica C Skarulis, M.D. | (301) 496-6087 | monicas@intra.niddk.nih.gov |
| United States, Maryland | |
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Recruiting |
| Bethesda, Maryland, United States, 20892 | |
| Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 prpl@mail.cc.nih.gov | |
| Principal Investigator: | Monica C Skarulis, M.D. | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
More Information
Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00896610 History of Changes |
| Other Study ID Numbers: | 090140, 09-DK-0140 |
| Study First Received: | May 8, 2009 |
| Last Updated: | May 1, 2013 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Institutes of Health Clinical Center (CC):
|
Diabetes Mellitus Type 1 Diabetes Complications Anti Beta-Cell Autoantibodies |
T-Lymphocyte Assays Type 2 Diabetes Autoimmune Diabetes At Risk Diabetes |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Glucose Metabolism Disorders |
Metabolic Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases |
ClinicalTrials.gov processed this record on May 23, 2013